257 results on '"Streicher, Katie"'
Search Results
52. Inhibition of Myogenic MicroRNAs 1, 133, and 206 by Inflammatory Cytokines Links Inflammation and Muscle Degeneration in Adult Inflammatory Myopathies
53. CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients
54. MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D
55. The Plasma Cell Signature in Autoimmune Disease
56. A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade
57. Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
58. Network Analysis of Gene Expression Profiles in Breast Cancer Cell Lines
59. Mammary Gland Immunity and Mastitis Susceptibility
60. Abstract 5718: miRNA-629: A circulating exosomal biomarker of NK cell function
61. Abstract 5544: Newcastle Disease Virus in human derived tumors: Understanding immune recruitment and activation via virally delivered IL-12
62. Abstract 911: Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR mutant NSCLC
63. Abstract 5667: Biomarkers associated with tertiary lymphoid structures are elevated in lung and bladder cancer patients who respond to durvalumab treatment
64. Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
65. Genomic signatures characterize leukocyte infiltration in myositis muscles
66. Abstract 3245: Durvalumab induces an NK cell response associated with clinical benefit of patients with advanced NSCLC
67. A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity
68. Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI‐551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease
69. Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
70. Abstract 4677: A new pipeline to predict and confirm tumor neo-antigens
71. Abstract 1007: Durvalumab + tremelimumab increase T cells and decrease expression of genes involved in angiogenesis, EMT, and the Th2 pathway in the NSCLC tumor microenvironment
72. Abstract 5390: microRNA signature of T cell exhaustion
73. Single-cell profiling of NSCLC tumor treated with Durvalumab and in combination with Tremelimumab.
74. Abstract 1773: A baseline IFNG gene expression signature correlates with clinical outcomes in durvalumab-treated advanced NSCLC cancer patients
75. Gene expression analysis of tumor biopsies from a trial of durvalumab to identify subsets of NSCLC with shared immune pathways.
76. Increased CD73 and reduced IFNG signature expression in relation to response rates to anti-PD-1(L1) therapies in EGFR-mutant NSCLC.
77. Development of a new ARCHITECT automated periostin immunoassay
78. Chapter 2 - Personalized Health Care (PHC) in Cancer
79. Dipeptidyl peptidase-4 (DPP-4) may predict response to tralokinumab in patients with asthma
80. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
81. Relationship of baseline tumoral IFNγ mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patients.
82. Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer
83. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE.
84. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial
85. A new investigational use only automated immunoassay for periostin
86. Abstract 4909: Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma
87. A microRNA Signature Predicts Response to Anti-CD19 Therapy (MEDI-551) in B-Cell Malignancies
88. Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia
89. Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma
90. CYP3A5genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients
91. The Plasma Cell Signature in Autoimmune Disease
92. Effect of microRNA-206 on G1 arrest by inhibition of CDK4, cyclin C, and cyclin D in melanoma cells.
93. Abstract 5268: Differential expression of insulin receptor isoforms in human lung cancer.
94. Altered Expression of Insulin Receptor Isoforms in Breast Cancer
95. Abstract 327: Altered expression of insulin receptor isoforms in breast cancer
96. A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children
97. Activation of a Nuclear Factor κB/Interleukin-1 Positive Feedback Loop by Amphiregulin in Human Breast Cancer Cells
98. Transforming properties of TC-1 in human breast cancer: Interaction with FGFR2 and β-catenin signaling pathways
99. Multiple Interacting Oncogenes on the 8p11-p12 Amplicon in Human Breast Cancer
100. Thioredoxin Reductase Regulates Angiogenesis by Increasing Endothelial Cell-Derived Vascular Endothelial Growth Factor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.